Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review
Open Access
- 1 December 2002
- journal article
- review article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 41 (12) , 1346-1356
- https://doi.org/10.1093/rheumatology/41.12.1346
Abstract
Earlier reports, including a comprehensive 1983 review, had indicated that slowing of radiographic progression was relatively unusual in treatment of rheumatoid arthritis (RA) using traditional disease modifying anti‐rheumatic drugs. However, in recent years, slowing of radiographic progression has been documented in a number of clinical trials, as well as long‐term observational studies, with use of (in alphabetical order) adalimumab, anakinra, corticosteroids, cyclophosphamide, cyclosporin, etanercept, gold salts, infliximab, leflunomide, methotrexate and sulphasalazine. At this time, disease modification is a realistic goal in the clinical care of patients with RA. Documentation of improved long‐term outcomes requires long‐term observational data over 5–20 yr to supplement data from randomized controlled clinical trials over 6–24 months.Keywords
This publication has 0 references indexed in Scilit: